F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comLaurus Labs Ltd is one of India’s leading pharmaceutical and biotechnology companies, with a strong presence across active pharmaceutical ingredients (APIs), formulations, and contract development and manufacturing (CDMO). Over the years, the company has transformed from being primarily an API-focused player to a diversified pharma company with growing capabilities in finished dosage formulations and biotech segments.
With increasing demand for affordable medicines, expansion into regulated markets, and rising global outsourcing of pharma manufacturing, Laurus Labs has positioned itself for long-term growth. In this article, we analyze Laurus Labs Ltd share price targets from 2026 to 2030 based on current market data, business fundamentals, shareholding pattern, and long-term sector outlook.
| Detail | Value |
|---|---|
| Open | ₹1,086.00 |
| Previous Close | ₹1,084.80 |
| Day’s High | ₹1,089.10 |
| Day’s Low | ₹1,080.70 |
| VWAP | ₹1,084.47 |
| Volume | 4,84,865 |
| Value (Lacs) | 5,239.94 |
| Market Capitalization | ₹58,342 Cr |
| 52-Week High | ₹1,092.60 |
| 52-Week Low | ₹501.15 |
| All-Time High | ₹1,092.60 |
| All-Time Low | ₹59.00 |
| UC Limit | ₹1,193.20 |
| LC Limit | ₹976.40 |
| Face Value | ₹2 |
| Book Value Per Share | ₹89.01 |
| Dividend Yield | 0.11% |
| Beta | 1.26 |
| 20D Avg Volume | 14,33,886 |
| 20D Avg Delivery (%) | 48.97% |
Laurus Labs Ltd operates across multiple pharmaceutical verticals, including:
Active Pharmaceutical Ingredients (APIs)
Finished Dosage Formulations (FDF)
Contract Development and Manufacturing Organization (CDMO)
Biotechnology and specialty ingredients
The company has built strong capabilities in antiretroviral (ARV), oncology, cardiovascular, and diabetes therapeutic segments. With manufacturing facilities approved by global regulators, Laurus Labs supplies products to both regulated and emerging markets.
Laurus Labs has reduced dependence on any single product category by expanding into formulations and CDMO, improving revenue stability.
The company exports to multiple international markets, including the US, Europe, and emerging economies, supporting long-term growth.
Increasing emphasis on oncology, biotech, and complex generics positions Laurus Labs well for future demand.
Continuous investments in research and development strengthen product pipeline and long-term competitiveness.
| Investor Type | Holding (%) |
|---|---|
| Retail and Others | 34.51% |
| Promoters | 27.59% |
| Foreign Institutions | 26.16% |
| Mutual Funds | 8.53% |
| Other Domestic Institutions | 3.20% |
A balanced shareholding structure with significant foreign institutional participation reflects confidence in Laurus Labs’ long-term growth prospects.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2026 | 1,250 | 1,350 |
| 2027 | 1,380 | 1,520 |
| 2028 | 1,550 | 1,700 |
| 2029 | 1,750 | 1,920 |
| 2030 | 2,000 | 2,200 |
These projections consider recovery in margins, growth in CDMO revenues, expansion in formulations, and favorable long-term pharma industry trends.
By 2026, Laurus Labs may benefit from stabilizing API prices and improving demand for formulations.
Growth Drivers:
Recovery in API margins
Growth in formulations exports
Improved capacity utilization
Investment View: Suitable for medium-term investors expecting steady recovery.
In 2027, stronger CDMO execution and product diversification could drive earnings growth.
Growth Drivers:
Expansion of CDMO order book
Entry into complex and high-value molecules
Improved operating leverage
Investment View: Attractive for long-term investors seeking pharma sector growth.
By 2028, Laurus Labs’ diversified portfolio may result in more stable and predictable cash flows.
Growth Drivers:
Strong demand from regulated markets
Growth in biotech and specialty segments
R&D-led product launches
Investment View: Suitable for investors seeking balanced growth with reduced volatility.
As global pharma outsourcing accelerates, Laurus Labs could see sustained revenue and profit expansion.
Growth Drivers:
Long-term contracts in CDMO business
Higher contribution from value-added formulations
Improved profitability and return ratios
Investment View: Favors long-term investors aiming for consistent compounding.
By 2030, Laurus Labs may emerge as a leading integrated pharma and CDMO player from India.
Growth Drivers:
Strong pipeline of complex generics and specialty products
Stable global client relationships
Enhanced margins and cash flow generation
Investment View: Ideal for long-term wealth creation in the pharmaceutical sector.
Laurus Labs Ltd offers long-term growth potential driven by diversification, global market expansion, and increasing focus on high-value pharmaceutical segments. While short-term volatility may arise due to pricing pressure or regulatory factors, the company’s fundamentals remain strong.
Diversified business model across APIs, formulations, and CDMO
Strong presence in regulated and emerging markets
Increasing focus on high-margin specialty segments
Solid institutional participation
Regulatory risks related to pharma manufacturing
Pricing pressure in generic drugs
Currency fluctuations impacting exports
Execution risks in new product launches
Monitoring quarterly results, regulatory updates, and industry trends is important before making investment decisions.
Laurus Labs Ltd has evolved into a diversified pharmaceutical company with strong long-term growth drivers. Supported by global demand for affordable medicines, expanding CDMO opportunities, and a robust product pipeline, the company is well-positioned for sustained growth. Based on current fundamentals and industry outlook, Laurus Labs Ltd share price could potentially reach between ₹2,000 and ₹2,200 by 2030. For investors seeking long-term exposure to India’s pharmaceutical growth story, Laurus Labs Ltd remains a promising option.
The share price is around the levels mentioned in the latest market data and varies with market conditions.
The expected target range for 2026 is ₹1,250 to ₹1,350.
Yes, for investors looking for long-term exposure to the pharmaceutical and CDMO sectors.
The projected target range for 2030 is ₹2,000 to ₹2,200.
Global pharma demand, API pricing, CDMO growth, regulatory approvals, and overall market sentiment.
Disclaimer: This article is for educational purposes only and does not constitute financial advice. Please consult a certified financial advisor before making any investment decisions.
Register & Login